Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR scree...

Descripción completa

Detalles Bibliográficos
Autores principales: Brien, Gerard L, Remillard, David, Shi, Junwei, Hemming, Matthew L, Chabon, Jonathon, Wynne, Kieran, Dillon, Eugène T, Cagney, Gerard, Van Mierlo, Guido, Baltissen, Marijke P, Vermeulen, Michiel, Qi, Jun, Fröhling, Stefan, Gray, Nathanael S, Bradner, James E, Vakoc, Christopher R, Armstrong, Scott A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2018
Materias:
Biochemistry and Chemical Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277197/
https://www.ncbi.nlm.nih.gov/pubmed/30431433
http://dx.doi.org/10.7554/eLife.41305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277197/
https://www.ncbi.nlm.nih.gov/pubmed/30431433
http://dx.doi.org/10.7554/eLife.41305

Ejemplares similares